keyword
MENU ▼
Read by QxMD icon Read
search

Psma

keyword
https://www.readbyqxmd.com/read/29045711/the-endothelial-prostate-specific-membrane-antigen-is-highly-expressed-in-gliosarcoma-and-visualized-by-68ga-psma-11-pet-a-theranostic-outlook-for-brain-tumor-patients
#1
Marcus Unterrainer, Maximilian Niyazi, Viktoria Ruf, Peter Bartenstein, Nathalie L Albert
No abstract text is available yet for this article.
October 17, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/29044297/psa-levels-psa-doubling-time-gleason-score-and-prior-therapy-cannot-predict-measured-uptake-of-68-ga-psma-hbed-cc-lesion-uptake-in-recurrent-metastatic-prostate-cancer
#2
Frederik A Verburg, David Pfister, Natascha I Drude, Felix M Mottaghy, Florian Behrendt
AIM: To assess whether clinical prostate cancer (PCA) related factors and therapy status can predict the degree of tracer uptake on [(68)Ga]PSMA-HBED-CC PET/CT. MATERIALS & METHODS: We retrospectively studied 124 patients with recurrent an/or metastatic PCA who underwent [(68)Ga]PSMA-HBED-CC PET/CT. The maximum standardized uptake value (SUVmax) was determined in the prostate bed as well as in three size categories (≤ 5 mm, > 5-15 mm, > 15 mm) in pelvic lymph node, extrapelvic lymph node, bone and visceral metastases...
October 18, 2017: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/29039420/kidney-cancer-psma-a-potential-therapeutic-target-in-rcc
#3
Michael A Gorin, Steven P Rowe
No abstract text is available yet for this article.
October 17, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29039196/a-mitochondria-targeted-ratiometric-biosensor-for-ph-monitoring-and-imaging-in-living-cells-with-congo-red-functionalized-dual-emission-semiconducting-polymer-dots
#4
Junyong Sun, Pinghua Ling, Feng Gao
The accurate and sensitive monitoring and imaging of mitochondrial pH in living cells play vital roles in chemical biology and biomedicine. Herein, we design a novel ratiometric fluorescent chemical probe for monitoring and imaging pH of mitochondria in living cells based on congo-red (CR)-modified dual-emission semiconducting polymer dots (Pdots) via a competitive fluorescence resonance energy transfer (FRET) mechanism. The Pdots are synthesized by triphenylphosphonium (TPP)-modified polyoxyethylene nonylphenylether (CO-520), Poly(9,9-dioctylfluorenyl-2,7-diyl) (PFO), poly(9,9-dioctylfluorene)-co-(4,7-di-2-thienyl-2,1,3-benzothiadiazole) (PF-DBT5), and poly(styrene-co-maleic anhydride) (PSMA) via nanoprecipitation method, and the prepared Pdots are further chemically linked with pH-sensitive, non-fluorescent CR to obtain the mitochondria-targeted pH fluorescent probes...
October 17, 2017: Analytical Chemistry
https://www.readbyqxmd.com/read/29038888/simultaneous-whole-body-18-f-psma-1007-pet-mri-with-integrated-high-resolution-multiparametric-imaging-of-the-prostatic-fossa-for-comprehensive-oncological-staging-of-patients-with-prostate-cancer-a-pilot-study
#5
Martin T Freitag, Claudia Kesch, Jens Cardinale, Paul Flechsig, Ralf Floca, Matthias Eiber, David Bonekamp, Jan P Radtke, Clemens Kratochwil, Klaus Kopka, Markus Hohenfellner, Albrecht Stenzinger, Heinz-Peter Schlemmer, Uwe Haberkorn, Frederik Giesel
INTRODUCTION: The aim of the present study was to explore the clinical feasibility and reproducibility of a comprehensive whole-body (18)F-PSMA-1007-PET/MRI protocol for imaging prostate cancer (PC) patients. METHODS: Eight patients with high-risk biopsy-proven PC underwent a whole-body PET/MRI (3 h p.i.) including a multi-parametric prostate MRI after (18)F-PSMA-1007-PET/CT (1 h p.i.) which served as reference. Seven patients presented with non-treated PC, whereas one patient presented with biochemical recurrence...
October 16, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29037965/prostate-cancer-specific-pet-radiotracers-a-review-on-the-clinical-utility-in-recurrent-disease
#6
Jaden D Evans, Krishan R Jethwa, Piet Ost, Scott Williams, Eugene D Kwon, Val J Lowe, Brian J Davis
Prostate cancer-specific positron emission tomography (pcPET) has been shown to detect sites of disease recurrence at serum prostate-specific antigen (PSA) levels that are lower than those levels detected by conventional imaging. Commonly used pcPET radiotracers in the setting of biochemical recurrence are reviewed including carbon 11/fludeoxyglucose 18 (F-18) choline, gallium 68/F-18 prostate-specific membrane antigen (PSMA), and F-18 fluciclovine. Review of the literature generally favors PSMA-based agents for the detection of recurrence as a function of low PSA levels...
July 20, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29036003/68ga-prostate-specific-membrane-antigen-avid-tubercular-lesions-mimicking-prostate-cancer-metastasis-on-simultaneous-prostate-specific-membrane-antigen-pet-mri
#7
Aashim Ahuja, Sangeeta Taneja, Kiran Thorat, Amarnath Jena
Ga-prostate-specific membrane antigen (PSMA) has gained increasing interest as a target molecule in imaging of prostate cancer because of its selective overexpression in local prostate cancer lesions and metastasis. We report a case of a 62-year-old man with raised serum prostate-specific antigen levels who presented for Ga-PSMA HBED-CC simultaneous PET/MRI for prostate cancer evaluation. A PSMA-nonavid PI-RADS 5 (Prostate Imaging-Reporting and Data System) lesion was confirmed as adenocarcinoma on histopathology...
October 13, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29035994/prostate-specific-membrane-antigen-in-low-grade-fibromatosis
#8
Ramin Akbarian Aghdam, Masoumeh Hakiminejad, Hamidreza Hashemifard, Azadeh Rakhshan, Elahe Pirayesh
We report a case of fibromatosis demonstrating prostate-specific membrane antigen (PSMA)-positive scan. A 76-year-old man was under assessment because of rising prostate-specific antigen level. Bone scan showed abnormal soft tissue uptake of Tc-MDP adjacent to the right scapula, compatible with a mass in MRI, thereafter. Because of the unavailability of Ga-PSMA scan in our department and also high cost in other centers, the patient underwent Lu-PSMA for more assessment, which revealed PSMA-avid mass. Pathologic examination confirmed the diagnosis of low-grade fibromatosis...
October 13, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29034176/imaging-tumour-thrombus-of-clear-cell-renal-cell-carcinoma-fdg-pet-or-psma-pet-direct-in%C3%A2-vivo-comparison-of-two-technologies
#9
Seyedehpariya Saadat, Bibiana Tie, Simon Wood, Ian Vela, Handoo Rhee
No abstract text is available yet for this article.
January 2018: Urology Case Reports
https://www.readbyqxmd.com/read/29032394/clinical-performance-of-68-ga-psma-11-pet-mri-for-the-detection-of-recurrent-prostate-cancer-following-radical-prostatectomy
#10
Benedikt Kranzbühler, Hannes Nagel, Anton S Becker, Julian Müller, Martin Huellner, Paul Stolzmann, Urs Muehlematter, Matthias Guckenberger, Philipp A Kaufmann, Daniel Eberli, Irene A Burger
PURPOSE: Sensitive visualization of recurrent prostate cancer foci is a challenge in patients with early biochemical recurrence (EBR). The recently established (68)Ga-PSMA-11 PET/CT has significantly improved the detection rate with published values of up to 55% for patients with a serum PSA concentration between 0.2-0.5 ng/mL. The increased soft tissue contrast in the pelvis using simultaneous (68)Ga-PSMA-11 PET/MRI might further improve the detection rate in patients with EBR and low PSA values over PET/CT...
October 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29029496/-177-lu-psma-617-radioligand-therapy-for-a-patient-with-lymph-node-metastatic-prostate-cancer
#11
Finn E von Eyben, Timo Kiljunen, Timo Joensuu, Kalevi Kairemo, Christian Uprimny, Irene Virgolini
Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer. PSMA is basis for new diagnostics and theranostics. PET/CT using PSMA is more sensitive than choline PET/CT. (177)Lu-PSMA radioligand therapy is mainly used for patients with end-stage prostate cancer. This report describes a patient with a third recurrence in lymph nodes. The recurrence was treated with (177)Lu-PSMA radioligand therapy instead of chemotherapy with docetaxel. The effect was in part evaluated relative to that of two established salvage treatments...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29028767/prostate-specific-membrane-antigen-guided-salvage-lymph-node-dissection-in-recurrent-prostate-cancer-a-novel-technology-to-detect-lymph-node-metastases
#12
Tobias Maurer, Jürgen E Gschwend, Matthias Eiber
PURPOSE OF REVIEW: With Gallium (Ga)-prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) as emerging imaging technique offering superior detection rates in biochemical recurrent prostate cancer, salvage lymph node dissection has gained increasing interest in localized oligometastatic prostate cancer. Currently, PSMA-targeting small molecules cannot only be linked to positron-emitting isotopes for imaging but also be labelled with γ-radiation emitting isotopes. These modified PSMA agents are evaluated for intraoperative guidance for resection of metastatic lymph nodes...
October 11, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/29026946/psma-targeted-radioligandtherapy-in-metastatic-castration-resistant-prostate-cancer-after-chemotherapy-abiraterone-and-or-enzalutamide-a-retrospective-analysis-of-overall-survival
#13
K Rahbar, M Boegemann, A Yordanova, M Eveslage, M Schäfers, M Essler, H Ahmadzadehfar
AIM: Our aim was to evaluate overall survival and parameters prognosticating longer survival in a large and homogeneous group of patients treated with (177)Lu-PSMA-617 radioligand therapy with heavily pretreated advanced metastatic castration resistant prostate cancer. METHODS: A total of 104 patients were treated with 351 cycles of (177)Lu-PSMA-617. Prostate specific antigen (PSA) changes after the first cycle of therapy were documented prior to a second cycle...
October 12, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29025989/low-level-endogenous-prostate-specific-membrane-antigen-psma-expression-in-non-prostatic-tumor-xenografts-is-sufficient-for-in-vivo-tumor-targeting-and-imaging
#14
Sridhar Nimmagadda, Mrudula Pullambhatla, Ying Chen, Princy Parsana, Ala Lisok, Samit Chatterjee, Ronnie Mease, Steven P Rowe, Shawn E Lupold, Kenneth J Pienta, Martin G Pomper
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and within the neovasculature of other solid tumors. The non-prostatic expression of PSMA has been reported exclusively within the neovasculature endothelial cells of non-prostate cancers, however, there are few reports on PSMA expression on epithelial cells. Herein we describe PSMA expression in non-prostatic epithelial cells and characterize the potential of PSMA-binding agents to non-invasively detect that expression. METHODS: PSMA expression data was extracted from publicly available genomic databases...
October 12, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29022058/-psma-radioguided-surgery-in-localised-recurrent-prostate-cancer
#15
REVIEW
T Horn, I Rauscher, M Eiber, J E Gschwend, T Maurer
Recently, prostate-specific membrane antigen radioguided surgery (PSMA-RGS) was introduced for targeted resection of localised prostate cancer recurrence. Preliminary results show that PSMA-RGS is very sensitive and specific in tracking suspicious lesions intraoperatively. Prerequisite for PSMA-RGS is a positive (68)Ga-PSMA positron emission tomography (PET) scan with a preferably singular soft tissue or lymph node recurrence. The first 63 patients treated with PSMA-RGS were analyzed. The extracorporal analysis of a total of 277 tissue specimens yielded the following test quality criteria regarding the presence of malignant tissue: sensitivity 86...
October 11, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28986618/-177-lu-psma-therapy-current-evidence-for-use-in-the-treatment-of-patients-with-metastatic-prostate-cancer
#16
REVIEW
M Boegemann, A J Schrader, K Rahbar
BACKGROUND: Despite significant progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in recent years (including agents targeting androgen receptor signaling, chemotherapy, and (223)Ra), most of these patients still succumb to prostate cancer. Recently, (177)lutetium prostate-specific membrane antigen radioligand therapy ((177)Lu-PSMA-RLT) has been increasingly used within compassionate use provisions in these patients in Germany and showed promising efficacy...
October 6, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28986512/cold-kit-psma-pet-imaging-phase-i-study-of-68-ga-thp-psma-pet-ct-in-patients-with-prostate-cancer
#17
Michael S Hofman, Peter Eu, Price Jackson, Emily Hong, David Binns, Amir Iravani, Declan Murphy, Catherine Mitchell, Shankar Siva, Rodney J Hicks, Jennifer D Young, Philip Blower, Gregory E Mullen
Objectives: Ga-68 labelled urea-based inhibitors of the prostate-specific membrane antigen (PSMA), such as (68)Ga-HBED-PSMA-11, are promising small molecules for targeting prostate cancer. A new radiopharmaceutical (68)Ga-THP-PSMA has a simplified design for one-step kit-based radiolabelling. It features the tris(hydroxypyridinone) (THP) ligand, which complexes (68)Ga3+ rapidly at low concentration, room temperature and over a wide pH range, enabling direct elution from a (68)Ge/(68)Ga generator into a lyophilized kit in one-step without manipulation...
October 6, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28986509/why-targeting-psma-is-a-game-changer-in-the-management-of-prostate-cancer-%C3%A2-a-urologist-s-point-of-view
#18
Nicholas M Donin, Robert Reiter
Prostate-specific membrane antigen (PSMA), is a transmembrane glycoprotein that is highly expressed on prostate adenocarcinomas, exhibits only limited expression in benign and extra-prostatic tissues, and thus represents an ideal target for the diagnosis and management of prostate cancer. Since its discovery over 30 years ago, significant effort has been made to develop clinical technology targeting PSMA. The last 5 years have seen an explosion of development of new agents targeting PSMA for diagnostic and therapeutic use...
October 6, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28980045/-the-role-of-psma-pet-ct-in-patients-with-metastatic-prostate-cancer
#19
REVIEW
J von Hardenberg, K-A Büsing, P Nuhn, M Ritter
Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) imaging for the localization of prostate cancer is increasingly available in Germany. The advances and limitations in different disease stages are reviewed. As the clinical relevance of oligometastatic disease in primary cancer detected by PSMA PET-CT imaging is not yet completely understood, it should only be used in clinical trials. In recurrent prostate cancer after therapy with curative intent, PSMA PET-CT shows encouraging potential for the planning of salvage therapy...
October 4, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28974599/molecular-radiotheragnostics-in-prostate-cancer
#20
Yong Du, Sabina Dizdarevic
Two different molecular radio-theragnostic principles are applied in prostate cancer, providing a personalised management for those patients. Firstly, radiopharmaceuticals with the same or similar mechanism of action but different energy (gamma-γ, eg (99m)Tc-diphosphonates or positron-β+, eg 18F-NaF emitting isotopes) can be used to identify patients with osteoblastic metastases for a treatment with bone seeking beta (β-) or alpha (α-) emitting radionuclides to deliver targeted molecular radiotherapy. A number of such β- emitting molecules have been used for bone palliation...
October 2017: Clinical Medicine: Journal of the Royal College of Physicians of London
keyword
keyword
5864
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"